09:53 AM EST - BriaCell Therapeutics Corp. : Is presenting clinical data from the pivotal Phase 3 study of its lead product candidate, Bria-IMT™, in metastatic breast cancer supporting the use of specific biomarkers to predict patients’ clinical response to Bria-IMT treatments. BriaCell Therapeutics Corp.
shares T.BCT are trading down $0.58 at $5.74.
